Antibodies zap both EBOV and SUDV Ebola strains
13 January 2016 | By Victoria White
Researchers have engineered the first antibodies that can potently neutralise the two deadliest strains of the virus that causes Ebola haemorrhagic fever...
List view / Grid view
News
An interview with Bernardo Perez-Ramirez, Sanofi, speaker at the 9th Annual Proteins & Antibodies Congress, 18-19 April 2016, London, UK
13 January 2016 | By Oxford Global
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations...
An interview with Elaine Pinheiro, Principal Scientist at MSD, speaker at the Advances in Immuno-oncology Congress, 12-13 May 2016, London, UK
13 January 2016 | By Oxford Global
Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment...
An interview with Uwe Gudat from Merck Serono, speaker at the 4th Annual Biosimilars & Biobetters Congress, 18-19 April 2016, London
13 January 2016 | By Oxford Global
In anticipation of our 4th Annual Biosimilars & Biobetters Congress, we spoke to one our expert speakers about the some of the key issues in the industry...
NIAID funds projects developing non-traditional therapeutics for bacterial infections
13 January 2016 | By Victoria White
NIAID has awarded $5 million in funding for 24 research projects to help address the growing health threat of antibiotic resistance...
Boehringer and Arena to advance research in psychiatric diseases
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
Pfizer expands its R&D investment strategy
12 January 2016 | By Victoria White
The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy...
Scientists design new CAR architecture with switch-on system
12 January 2016 | By Victoria White
A new study describes the design of a CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions...
MSD acquires drug discovery company IOmet
12 January 2016 | By Victoria White
The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...
Vagus nerve stimulation shown to suppress CSDs – a trigger for migraine
12 January 2016 | By Victoria White
Cortical spreading depressions (CSDs) are believed to be responsible for the aura, or visual disturbance, that frequently precedes some migraines, and have been a significant target for pharmaceutical development...
Preclinical data for ReNeuron’s exosome nanomedicine platform published
12 January 2016 | By Victoria White
ReNeuron is researching the therapeutic potential of exosomes derived from its proprietary stem cell lines. The Company is also exploring the potential of its exosomes as a delivery system for gene therapy treatments...
Sanofi and Warp Drive Bio team up to discover oncology therapeutics and antibiotics
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...
AstraZeneca and Moderna enter mRNA therapy collaboration
11 January 2016 | By Victoria White
mRNA-based therapies are an innovative treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases...
Aelix completes €11.5 M Series A funding for therapeutic HIV vaccine
11 January 2016 | By Victoria White
The proceeds will support the development of Aelix’s lead candidate HTI immunogen as a therapeutic vaccine against HIV infection up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individuals...
Novartis expands immuno-oncology pipeline with Surface Oncology alliance
11 January 2016 | By Victoria White
The agreement gives Novartis access to four preclinical programmes that target regulatory T-cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment...
